

Consultants Report: Q3 2025

SJVIA- EmpiRx Health – Q3 2025 Highlights

• SJVIA's total plan cost increased by 4% in Q3 2025


	Q2 2025	Q3 2025	QoQ Change
SJVIA	\$9,784,845	\$10,184,947	4%
Tulare	\$4,053,063	\$4,272,075	5%
Fresno	\$5,731,782	\$5,912,872	3%

While overall Script Count increased there were count decreases in all Retail Generic, Retail90 Brand & Specialty

Category	SJVIA Q2 2025	SJVIA Q3 2025	QoQ Change	Tulare Q2 2025	Tulare Q3 2025	QoQ Change	Fresno Q2 2025	Fresno Q3 2025	QoQ Change
Retail Brand	4,363	5,431	1,068	1,927	2,315	388	2,436	3,116	680
Retail Generic	16,985	16,277	(708)	6,846	6,593	(253)	10,139	9,684	(455)
Retail 90 Brand	1,069	1,048	(21)	369	357	(12)	700	691	(9)
Retail 90 Generic	8,748	8,815	67	3,367	3,346	(21)	5,381	5,469	88
Mail Brand	104	139	35	58	63	5	46	46 76	
Mail Generic	318	384	66	138	181	43	180	203	23
Specialty	868	826	(42)	292	273	(19)	576	553	(23)
TOTAL	32,455	32,920	465	12,997	13,128	131	19,458	19,792	334

• Specialty claims plan cost decreased in Q3 2025

Category	SJVIA Q2 2025	SJVIA Q3 2025	QoQ Change	Tulare Q2 2025	Tulare Q3 2025	QoQ Change	Fresno Q2 2025	Fresno Q3 2025	QoQ Change
Retail Brand	\$3,822,493	\$4,533,356	\$710,863	\$1,740,307	\$2,052,269	\$311,962	\$2,082,186	\$2,481,087	\$398,901
Retail Generic	\$572,586	\$541,785	(\$30,801)	\$230,366	\$211,835	(\$18,531)	\$342,220	\$329,950	(\$12,271)
Retail 90 Brand	\$1,370,500	\$1,345,398	(\$25,102)	\$452,961	\$445,085	(\$7,876)	\$917,539	\$900,313	(\$17,226)
Retail 90 Generic	\$525,346	\$508,563	(\$16,783)	\$208,647	\$202,082	(\$6,566)	\$316,699	\$306,481	(\$10,218)
Mail Brand	\$163,396	\$236,283	\$72,887	\$89,752	\$103,865	\$14,113	\$73,645	\$132,419	\$58,774
Mail Generic	\$27,738	\$36,513	\$8,776	\$12,777	\$18,864	\$6,087	\$14,961	\$17,650	\$2,689
Specialty	\$3,302,785	\$2,983,049	(\$319,736)	\$1,318,253	\$1,238,076	(\$80,177)	\$1,984,533	\$1,744,973	(\$239,560)



SJVIA- EmpiRx Health – Q3 2025 Highlights

Enrollment Changes

	Jun-25	Sep-25	QoQ Change
SJVIA	13,583	13,578	(5)
Tulare	4,752	4,783	31
Fresno	8,831	8,795	(36)

• Patient Saver Plus Program Savings (formerly known as Variable Copay Assistance (VCAP) aka bWell)


	May 2025 - Sept 2025
SJVIA	\$562,621
Tulare	\$203,629
Fresno	\$358,992

Rebates

Q1 - 2025	\$1,755,770
Q2 - 2025	\$2,175,410
Q3 - 2025	Due by January 8, 2026
Q4 - 2025	Due by April 10, 2026

• Estimated Clinical Savings: Annual Guarantee is \$1,800,000


Q1 - 2025	\$1,051,335
Q2 - 2025	\$2,070,405
Q3 - 2025	Due by January 8, 2026
Q4 - 2025	Due by April 10, 2026



Top Clinical Cost Drivers by Drug Q1 – Q3 2025

Top Drugs by Ingredient Cost
Based on Paid Date: 01/01/2025-09/30/2025

Drug Label Name	Drug Group	Brand	Formulary	Specialty	Claim	Utilizers	Ingredient
		Generic Indicator	Tier	Indicator	Count		Cost
		mulcator					
WEGOVY	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	В	3	N	2,170	420	\$3,075,822.86
ZEPBOUND	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	В	3	N	2,217	494	\$2,596,725.48
MOUNJARO	ANTIDIABETICS	В	2	N	1,697	322	\$2,219,636.07
OZEMPIC	ANTIDIABETICS	В	2	N	1,987	586	\$2,541,295.21
DUPIXENT	DERMATOLOGICALS	В	2	Y	260	38	\$1,097,547.60
JARDIANCE	ANTIDIABETICS	В	2	N	434	168	\$631,049.74
HUMIRA	ANALGESICS - ANTI-INFLAMMATORY	В	2	Y	58	11	\$444,466.26
RINVOQ	ANALGESICS - ANTI-INFLAMMATORY	В	2	Y	59	11	\$429,762.74
SKYRIZI PEN	DERMATOLOGICALS	В	2	Y	18	9	\$410,549.92
EMPAVELI	HEMATOLOGICAL AGENTS - MISC.	В	2	Y	10	1	\$404,894.26
JYNARQUE	ENDOCRINE AND METABOLIC AGENTS - MISC.	В	3	Y	17	2	\$381,805.60
BIKTARVY	ANTIVIRALS	В	2	Y	75	12	\$321,038.01
ELIQUIS	ANTICOAGULANTS	В	2	N	271	86	\$311,699.91
STELARA	DERMATOLOGICALS	В	2	Y	11	4	\$296,809.71
TREMFYA ONE-PRESS	DERMATOLOGICALS	В	2	Y	20	9	\$296,353.08
FARXIGA	ANTIDIABETICS	В	2	N	172	78	\$260,919.53
TREMFYA	DERMATOLOGICALS	В	2	Y	17	7	\$250,899.63
RYBELSUS	ANTIDIABETICS	В	2	N	147	41	\$243,275.25
TRULICITY	ANTIDIABETICS	В	2	N	161	44	\$237,565.48
PAXLOVID (300/100)	ANTIVIRALS	В	2	N	153	170	\$234,469.31
SPRYCEL	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	В	3	Y	15	2	\$229,123.72
NURTEC	MIGRAINE PRODUCTS	В	2	N	130	39	\$217,239.80
ICLUSIG	ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	В	2	Y	9	1	\$215,005.44



Pharmacy Market Updates

Oral GLP-1 Medications in Development

- Several oral GLP-1 medications are in development, with potential FDA approval in the coming years.
- o **Oral Wegovy®** (higher-dose semaglutide): The manufacturer has submitted an application for a higher-dose oral semaglutide specifically for weight loss, with a decision expected in late 2025.
- Orforglipron: This is a promising, next-generation, non-peptide GLP-1 receptor agonist developed by Eli Lilly that is taken as a daily pill and does not require specific timing around meals. Clinical trials have shown significant results for both type 2 diabetes and weight loss, and the manufacturer aims for regulatory approval in late 2025 or 2026
- Danuglipron: Development of this once-daily oral tablet was discontinued by Pfizer in 2025 due to concerns over side effects and potential liver injury signals.
- The only oral GLP-1 medication currently FDA-approved and available on the market is Rybelsus® (oral semaglutide), which is indicated for the treatment of type 2 diabetes.

